|
Market Closed -
Nasdaq
16:00:00 2026-10-27 EDT
|
5-day change | 1st Jan Change | ||
| 2.600 USD | +8.33% |
|
+0.78% | +26.83% |
| 10-08 | Editas Medicine Shares Rise After Australia Clears Phase 1/2 Trial of EDIT-401 | MT |
| 10-08 | Wells Fargo Upgrades Editas Medicine to Overweight From Equal Weight, $6 Price Target | MT |
| Market Cap | 399M 358M 331M 300M 561M 37.93B 568M 3.97B 1.58B 19.88B 1.5B 1.47B 63.04B | P/E 2026 * |
-3.32x | P/E 2027 * | -3.61x |
|---|---|---|---|---|---|
| Enterprise Value | 263M 236M 218M 197M 369M 24.95B 373M 2.61B 1.04B 13.08B 986M 965M 41.47B | EV / Sales 2026 * |
10.2x | EV / Sales 2027 * | 13.5x |
| Free-Float |
99.82% | Yield 2026 * |
-
| Yield 2027 * | - |
| Markets | Quality | ||
|---|---|---|---|
Nasdaq
| EDIT | Delayed | |
CBOE
| EDIT | Real-time | |
|
Tradegate
| 8EM | Real-time | |
|
Berne S.E.
| 8EM | End-of-day quote | |
|
Deutsche Boerse AG
| 8EM | Delayed | |
|
Börse Stuttgart
| 8EM | Delayed | |
|
Boerse Muenchen
| 8EM | Real-time |
Last Transcript: Editas Medicine, Inc.
| 1 day | +8.33% | ||
| 1 week | +0.78% | ||
| Current month | +1.17% | ||
| 1 month | +0.78% | ||
| 3 months | -2.99% | ||
| 6 months | -10.03% | ||
| Current year | +26.83% |
| 1 week | 2.3 |  | 2.61 |
| 1 month | 2.24 | | 2.97 |
| Current year | 1.66 | | 3.94 |
| 1 year | 1.66 | | 3.94 |
| 3 years | 0.91 | | 11.69 |
| 5 years | 0.91 | | 42.11 |
| 10 years | 0.91 | | 99.95 |
| Manager | Title | Age | Since |
|---|---|---|---|
Gilmore O’Neill
CEO | Chief Executive Officer | 61 | 2022-05-31 |
Amy Parison
DFI | Director of Finance/CFO | 40 | 2025-03-27 |
Daniel Ory
CTO | Chief Tech/Sci/R&D Officer | - | 2026-09-07 |
| Director | Title | Age | Since |
|---|---|---|---|
Andrew Hirsch
BRD | Director/Board Member | 55 | 2017-05-29 |
Jessica Hopfield
CHM | Chairman | 61 | 2024-12-30 |
David Scadden
BRD | Director/Board Member | 73 | 2019-02-05 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 9/8/26 | Free | Chief Technology Officer | 950,000 | 0.6186% | ||
| 9/3/26 | Sell | Chief Financial Officer | -453 | 0.0003% | ||
| 9/3/26 | Sell | Chief Executive Officer | -5,124 | 0.0033% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +8.33% | +0.78% | -20.00% | -58.47% | 369M | |
| -3.10% | -4.19% | +32.67% | +59.47% | 65.28B | |
| +0.33% | +0.33% | +10.16% | +78.07% | 54.57B | |
| +0.16% | +1.73% | +9.89% | +102.10% | 53.59B | |
| -0.75% | +1.38% | +24.89% | +50.91% | 45.03B | |
| -1.30% | -4.80% | +16.05% | +114.76% | 42.17B | |
| +1.26% | -5.26% | +221.12% | +900.64% | 39.42B | |
| -0.74% | -4.46% | +11.00% | +44.65% | 32.71B | |
| +2.87% | -7.00% | +24.97% | -9.03% | 24.01B | |
| +1.11% | +15.18% | +60.27% | +49.33% | 26.5B | |
| Average | +0.82% | -0.07% | +39.10% | +133.24% | 38.36B | |
| Weighted average by Cap. | -0.36% | -0.58% | +42.43% | +153.20% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 25.79M 23.15M 21.38M 19.38M 36.23M 2.45B 36.67M 256M 102M 1.28B 96.82M 94.75M 4.07B | 19.46M 17.46M 16.13M 14.62M 27.33M 1.85B 27.67M 193M 76.78M 969M 73.04M 71.48M 3.07B |
| Net income | -95.2M -85.44M -78.89M -71.54M -134M -9.04B -135M -946M -376M -4.74B -357M -350M -15.03B | -121M -108M -100M -90.72M -170M -11.47B -172M -1.2B -476M -6.01B -453M -443M -19.06B |
| Net Debt | -137M -123M -113M -103M -192M -12.98B -194M -1.36B -539M -6.8B -513M -502M -21.57B | -138M -123M -114M -103M -193M -13.07B -196M -1.37B -543M -6.85B -516M -505M -21.72B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-10-27 | US$2.600 | +8.33% | 3,078,363 |
| 26-10-26 | US$2.400 | 0.00% | 1,350,904 |
| 26-10-23 | US$2.400 | -3.61% | 1,313,712 |
| 26-10-22 | US$2.490 | -0.80% | 1,066,486 |
| 26-10-21 | US$2.510 | -2.71% | 1,139,426 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- EDIT Stock
Select your edition
All financial news and data tailored to specific country editions
